The USFDA has approved the first anti-inflammatory atheroprotective cardiovascular drug, colchicine, to decrease the risk of myocardial infarction (MI), coronary revascularization, stroke, and cardiovascular death in adult patients diagnosed with atherosclerotic disease or having cardiovascular disease risk factors. The approval was granted based on the findings of a clinical trial in which daily administration of 0.5 mg of colchicine decreased the composite risk of cardiovascular death and spontaneous MI, ischemic-driven coronary revascularization, and ischemic stroke by 31% in chronic coronary disease patients who were on standard care, including statins.
Mechanism of action of colchicine Inhibits b-tubulin polymerization to form microtubules and thus disrupts cytoskeletal functions Blocks the activation, migration, and degranulation of neutrophils Decreases high-sensitivity…
